President Trump Secures Deal to Reduce Weight Loss Drug Prices
President Donald Trump has announced a landmark agreement with pharmaceutical powerhouses Eli Lilly and Novo Nordisk. This deal will significantly reduce the prices of popular weight loss drugs, including Wegovy and Zepbound. As a result, monthly costs could fall from over $1,000 to a range of $245-$350 for eligible patients.
As part of the agreement:
- Medicare and Medicaid beneficiaries will see their monthly copays reduced to just $50.
- Customers using the new TrumpRx platform can purchase these drugs for approximately $350 per month, a significant reduction from the current $1,350 price tag.
- The pharmaceutical companies have pledged to offer upcoming oral versions of these GLP-1 drugs at a monthly cost of $149, once they receive FDA approval.
“Today marks a pivotal moment in U.S. health care policy,” stated Eli Lilly CEO David A. Ricks. The new pricing structure is set to take effect in January 2026, potentially expanding access to these vital medications for millions of Americans battling obesity and diabetes.
Move to the category: